Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis

• Published in: Pharmacology & therapeutics (Oxford) Vol. 243; p. 108358
• Main Authors: Pilipović, Ivan, Stojić-Vukanić, Zorica, Leposavić, Gordana
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.03.2023
• Subjects: Animals; Beta-adrenoceptor blockade; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Encephalomyelitis, Autoimmune, Experimental - pathology; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Male; Microglia; Microglia activation/polarization; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - pathology; Norepinephrine; Primary autoimmune response; Propranolol - therapeutic use; Rats; Receptors, Adrenergic - therapeutic use; Sympathetic nervous system activation; Th17-cell reactivation; CX3CR1; TAM; Multiple sclerosis; SSRIs; JNK; GPR41; CNS; mRNA; HO-1; Th17-cell reactivation; Socs; cAMP; CX3CL1; IFN; Beta-adrenoceptor blockade; NF-κB; Stat; Th; CAs; Nrf2; GM-CSF; EBV; SNS; NARIs; CD; Primary autoimmune response; IL; Covid-19; MS; Tregs; TCAs; Sympathetic nervous system activation; PKA; EAE; FKN; HMG-CoA; MAPK; CIS; CCL; RA; Microglia activation/polarization; MAO; Sirt1; IRF; ERK
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2023.108358

This review summarizes recent findings related to the role of the sympathetic nervous system (SNS) in pathogenesis of multiple sclerosis (MS) and its commonly used experimental model – experimental autoimmune encephalomyelitis (EAE). They indicate that noradrenaline, the key end-point mediator of the SNS, acting through β-adrenoceptor, has a contributory role in the early stages of MS/EAE development. This stage is characterized by the SNS hyperactivity (increased release of noradrenaline) reflecting the net effect of different factors, such as the disease-associated inflammation, stress, vitamin D hypovitaminosis, Epstein-Barr virus infection and dysbiosis. Thus, the administration of propranolol, a non-selective β-adrenoceptor blocker, readily crossing the blood-brain barrier, to experimental rats before the autoimmune challenge and in the early (preclinical/prodromal) phase of the disease mitigates EAE severity. This phenomenon has been ascribed to the alleviation of neuroinflammation (due to attenuation of primarily microglial activation/proinflammatory functions) and the diminution of the magnitude of the primary CD4+ T-cell autoimmune response (the effect associated with impaired autoantigen uptake by antigen presenting cells and their migration into draining lymph nodes). The former is partly related to breaking of the catecholamine-dependent self-amplifying microglial feed-forward loop and the positive feedback loop between microglia and the SNS, leading to down-regulation of the SNS hyperactivity and its enhancing influence on microglial activation/proinflammatory functions and the magnitude of autoimmune response. The effects of propranolol are shown to be more prominent in male EAE animals, the phenomenon important as males (like men) are likely to develop clinically more severe disease. Thus, these findings could serve as a firm scientific background for formulation of a new sex-specific immune-intervention strategy for the early phases of MS (characterized by the SNS hyperactivity) exploiting anti-(neuro)inflammatory and immunomodulatory properties of propranolol and other relatively cheap and safe adrenergic drugs with similar therapeutic profile.